Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.48 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | GSR | P00390 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1071384 | 1.00 | SLC15A2 (0.48) | SLC15A2ERAP2LNPEPFOLH1ECE1 | |
| SCHEMBL29940001 | 0.98 | SLC15A2 (0.49) | SLC15A2ERAP2LNPEPFOLH1ECE1 | |
| Glycine SCHEMBL22289294 | 0.98 | SLC15A2 (0.49) | SLC15A2ERAP2LNPEPFOLH1ECE1 | |
| SCHEMBL31453801 | 0.97 | SLC15A2 (0.51) | SLC15A2ERAP2LNPEPFOLH1ECE1 | |
| SCHEMBL29849009 | 0.97 | SLC15A2 (0.51) | SLC15A2ERAP2LNPEPFOLH1ECE1 | |
| SCHEMBL29519574 | 0.95 | SLC15A2 (0.47) | SLC15A2ERAP2LNPEPFOLH1ECE1 | |
| SCHEMBL29588307 | 0.95 | SLC15A2 (0.47) | SLC15A2ERAP2LNPEPFOLH1ECE1 | |
| Glycine SCHEMBL28311057 | 0.95 | SLC15A2 (0.47) | SLC15A2ERAP2LNPEPFOLH1ECE1 | |
| SCHEMBL31453794 | 0.94 | SLC15A2 (0.46) | SLC15A2ERAP2LNPEPFOLH1ECE1 | |
| SCHEMBL31453805 | 0.94 | SLC15A2 (0.46) | SLC15A2ERAP2LNPEPFOLH1ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014265-A1 | TRIPLE-PAYLOAD ANTIBODY-DRUG CONJUGATES (ADCs) | ARARIS BIOTECH AG (CH) | 2026-01-15 | — | — | US | claimed |
| CN-116807990-B | Esomeprazole magnesium enteric capsule and preparation method thereof | 桂林华信制药有限公司 | 2024-09-24 | — | — | CN | claimed |
| CN-118243806-A | Application of metabolic marker in preparation of acute myocardial infarction product identification | 山东第一医科大学(山东省医学科学院) | 2024-06-25 | — | — | CN | claimed |
| WO-2024104138-A1 | N-TERMINAL FUNCTIONALIZATION-MODIFIED CYSTYL DIOLEYLAMINE COMPOUND, CHEMICAL SYNTHESIS METHOD THEREFOR, AND USE THEREOF | 北京大学 | 2024-05-23 | — | — | WO | claimed |
| CN-117720617-A | Synthesis process of acetyl tetrapeptide-3 | 山东济肽生物科技有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-117126230-B | Synthesis method and application of tripeptide-1 and blue copper peptide | 广州同隽医药科技有限公司 | 2024-02-13 | — | — | CN | claimed |
| CN-117126230-A | Synthesis method and application of tripeptide-1 and blue copper peptide | 广州同隽医药科技有限公司 | 2023-11-28 | — | — | CN | claimed |
| CN-116807990-A | Esomeprazole magnesium enteric capsule and preparation method thereof | 桂林华信制药有限公司 | 2023-09-29 | — | — | CN | claimed |
| CN-116789734-A | Oligopeptide group extracted from crayfish shells, extraction method and application thereof | 奇明达(北京)植物药物技术开发有限公司 | 2023-09-22 | — | — | CN | claimed |
| CN-116390938-A | Exendin-4 analogues | TXP制药股份有限公司 | 2023-07-04 | — | — | CN | claimed |
| CN-114891063-B | Liquid phase synthesis method of palmitoyl tripeptide-1 | 浙江湃肽生物股份有限公司 | 2023-06-13 | — | — | CN | claimed |
| CN-116143867-A | Method for preparing GHK tripeptide and blue copper peptide without condensing agent | 上海锐康生物技术研发有限公司 | 2023-05-23 | — | — | CN | claimed |
| CN-114891063-A | Liquid phase synthesis method of palmitoyl tripeptide-1 | 浙江湃肽生物股份有限公司 | 2022-08-12 | — | — | CN | claimed |
| CN-114380695-A | Novel method for simply and quickly realizing C-C bond forming reaction | 吉林大学 | 2022-04-22 | — | — | CN | claimed |
| CN-103344592-A | Determining method for GHK (Glycyl-L-Histidyl-L-Lysine) content | UNIV QILU TECHNOLOGY | 2013-10-09 | — | — | CN | claimed |
| JP-60248618-A | — | — | None | — | — | JP | disclosed |
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2006106528-A1 | NOVEL PEPTIDES USEFUL FOR TREATMENT OF ALOPECIA | DABUR PHARMA LIMITED (IN) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006091101-A2 | GELATION OF ANIONIC POLYSACCARIDES USING PROTEIN HYDROLYSATES | CSM NEDERLAND B.V. (NL) | 2006-08-31 | — | — | WO | disclosed |
| JP-S60248618-A | DIPEPTIDE-CONTAINING REMEDY FOR ULCER | NIPPON ZOKI PHARMACEUT CO LTD | 1985-12-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014265-A1 | TRIPLE-PAYLOAD ANTIBODY-DRUG CONJUGATES (ADCs) | TOP2A, TOP1, TOP2B | SLC15A2 700/4885ERAP2 3097/4885LNPEP 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.